ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2012

Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Jill M Siegfried et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.